Deals

Deal activity by volume related to ESG increased by 86% year-on-year in 2022 in the medical industry

Powered by

Analysis of the key themes driving deal activity reveals that ESG accounted for 314 pharmaceutical deals between 2018 and 2022, worth a total value of $131,024m, according to GlobalData’s Deals database Analysis of the key themes driving deal activity reveals that ESG accounted for 126 medical deals between 2018 and 2022, worth a total value of $11,095m, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships. The $75m venture financing issue by RapidSOS was the largest disclosed deal in 2022, while the $15m venture financing issue by Hemanext was the largest disclosed deal in 2021.  

In volume terms, ESG-related deal activity increased by 86% year-on-year in 2022, whereas it decreased by 83% year-on-year in 2021.  

Deal activity related to ESG in the global medical industry in the last five years

Top deals related to ESG in the medical industry in the last five years

Deal volume by deal type for ESG related deals in the medical industry in the last five years  

Partnerships accounted for the highest number of deals in the last five years, with 41 deals, followed by venture financing (27 deals) and acquisitions (21 deals).

Top financial advisors for ESG related deals by value in the medical industry in the last five years  

The top financial advisors supporting deals related to ESG in the medical industry in the last five years in terms of value were Goldman Sachs International, Barclays Wealth Management, Deutsche Bank, J.P. Morgan Cazenove, and Rothschild.

Top legal advisors for ESG related deals by value in the medical industry in the last five years  

The top legal advisors supporting deals related to ESG in the medical industry in the last five years in terms of value were Allen & Overy, Arnold & Porter Kaye Scholer, Shearman & Sterling, Simpson Thacher & Bartlett, and Travers Smith.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements. 

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.  

Go to article: Home | AI is reimagining imaging, but how far can we go today?Go to article: Editor's letterGo to article: ContentsGo to article: Alleima Company InsightGo to article: AlleimaGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Apple RubberGo to article: mdi ConsultantsGo to article: In DepthGo to article: AI is reimagining imaging, but how far can we go today? Go to article: Understanding updates on medical device labelling Go to article: Mass spectrometry and photometry for rAAV vector characterisation   Go to article: More than just meetings? Zoom scales ambitions in telehealth Go to article: Breathing easy: How digital inhalers are changing asthma treatment  Go to article: The cost of companion diagnostics in oncology Go to article: Formacoat Company InsightGo to article: FormacoatGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: Foreword: ESG moves up the agendaGo to article: ESG is the most important theme of this decadeGo to article: A timeline of corporate ESGGo to article: The most pressing ESG concerns for the medical device industryGo to article: Key trends impacting ESG performance in the medical device sectorGo to article: Latest news: ESG in medical devicesGo to article: Q&A with GlobalData thematic analystGo to article: Sustainable supply chains: Clinical trials in a new era of limited resources  Go to article: GlobalData highlights the need for ESG commitment by medical device companies Go to article: Leading medical companies in the ESG theme Go to article: Environmental sustainability innovation: leading companies in biomedical 3D prinGo to article: Deal activity related to ESG in the medical industry since 2020Go to article: ESG hiring trends in the global medical industry since 2020 Go to article: ESG patent applications in the global medical industry since 2020Go to article: Mentions of ESG in medical industry company filings since 2020Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored supplementsGo to article: WatlowGo to article: Mimotopes Company InsightGo to article: ListingsGo to article: EventsGo to article: Get ready for the Medical Device Network Excellence Awards Go to article: Buyer's GuidesGo to article: Next issue